{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:14:19Z","timestamp":1770815659745,"version":"3.50.1"},"reference-count":34,"publisher":"Japanese Pharmacological Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pharmacol Sci"],"published-print":{"date-parts":[[2008]]},"DOI":"10.1254\/jphs.fm0070141","type":"journal-article","created":{"date-parts":[[2008,1,23]],"date-time":"2008-01-23T05:51:12Z","timestamp":1201067472000},"page":"2-8","source":"Crossref","is-referenced-by-count":34,"title":["Neuropsychotoxicity of Abused Drugs: Molecular and Neural Mechanisms of Neuropsychotoxicity Induced by Methamphetamine, 3,4-Methylenedioxymethamphetamine (Ecstasy), and 5-Methoxy-N,N-diisopropyltryptamine (Foxy)"],"prefix":"10.1254","volume":"106","author":[{"given":"Takayuki","family":"Nakagawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"332","reference":[{"issue":"7","key":"1","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1523\/JNEUROSCI.12-07-02439.1992","volume":"12","year":"1992","ISSN":"https:\/\/id.crossref.org\/issn\/0270-6474","issn-type":"print"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.5.1817"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 White SR, Obradovic T, Imel KM, Wheaton MJ. The effects of methylenedioxymethamphetamine (MDMA, “Ecstasy”) on monoaminergic neurotransmission in the central nervous system. Prog Neurobiol. 1996;49:455–479.","DOI":"10.1016\/0301-0082(96)00027-5"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Fantegrossi WE, Harrington AW, Kiessel CL, Eckler JR, Rabin RA, Winter JC, et al. Hallucinogen-like actions of 5-methoxy-N,N<\/i>-diisopropyltryptamine in mice and rats. Pharmacol Biochem Behav. 2006;83:122–129.","DOI":"10.1016\/j.pbb.2005.12.015"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2006.11.075"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Sogawa C, Sogawa N, Tagawa J, Fujino A, Ohyama K, Asanuma M, et al. 5-Methoxy-N,N<\/i>-diisopropyltryptamine (Foxy), a selective and high affinity inhibitor of serotonin transporter. Toxicol Lett. 2007;170:75–82.","DOI":"10.1016\/j.toxlet.2007.02.007"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2005.03485.x"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Ago Y, Nakamura S, Uda M, Kajii Y, Abe M, Baba A, et al. Attenuation by the 5-HT1A receptor agonist osemozotan of the behavioral effects of single and repeated methamphetamine in mice. Neuropharmacology. 2006;51:914–922.","DOI":"10.1016\/j.neuropharm.2006.06.001"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Müller CP, Carey RJ, Huston JP, De Souza Silva MA. Serotonin and psychostimulant addiction: focus on 5-HT1A<\/sub>-receptors. Prog Neurobiol. 2007;81:133–178.","DOI":"10.1016\/j.pneurobio.2007.01.001"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0600839103"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2728(93)90109-S"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(00)80213-5"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1038\/nature03978"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Yamauchi Y, Izumi T, Unemura K, Uenishi Y, Nakagawa T, Kaneko S. Acceleration of serotonin transporter transport-associated current by 3,4-methylenedioxymethanphetamine (MDMA) under acidic conditions. Neurosci Lett. 2007;428:72–76.","DOI":"10.1016\/j.neulet.2007.09.037"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(88)90056-8"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Gramsbergen JB, Cumming P. Serotonin mediates rapid changes of striatal glucose and lactate metabolism after systemic 3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”) administration in awake rats. Neurochem Int. 2007;51:8–15.","DOI":"10.1016\/j.neuint.2007.03.004"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0173(97)00021-0"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(00)00174-X"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Robinson TE, Jurson PA, Bennett JA, Bentgen KM. Persistent sensitization of dopamine neurotransmission in ventral striatum (nucleus accumbens) produced by prior experience with (+)-amphetamine: a microdialysis study in freely moving rats. Brain Res. 1988;462:211–222.","DOI":"10.1016\/0006-8993(88)90549-5"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Vanderschuren LJ, Kalivas PW. Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies. Psychopharmacology. 2000;151:99–120.","DOI":"10.1007\/s002130000493"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Maeda T, Fukazawa Y, Shimizu N, Ozaki M, Yamamoto H, Kishioka S. Electrophysiological characteristic of corticoaccumbens synapses in rat mesolimbic system reconstructed using organotypic slice cultures. Brain Res. 2004;1015:34–40.","DOI":"10.1016\/j.brainres.2004.04.033"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0270(91)90128-M"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Fallon JH, Moore RY. Catecholamine innervation of basal forebrain. IV. Topography of the dopamine projection to the basal forebrain and striatum. J Comp Neurol. 1978;180:545–580.","DOI":"10.1002\/cne.901800310"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Sesack SR, Deutch AY, Roth RH, Bunney BS. Topographical organization of the efferent projections of the medial prefrontal cortex in rat: an anterograde tract-tracing study with Phaseolus vulgaris leucoagglutinin. J Comp Neurol. 1989;290:213–242.","DOI":"10.1002\/cne.902900205"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Wolf ME. The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants. Prog Neurobiol. 1998;54:679–720.","DOI":"10.1016\/S0301-0082(97)00090-7"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 White FJ, Wang RY. Electrophysiological evidence for A10 dopamine autoreceptor sensitivity following chronic d-amphetamine treatment. Brain Res. 1984;309:283–292.","DOI":"10.1016\/0006-8993(84)90594-8"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Ohmori T, Abekawa T, Muraki A, Koyama T. Competitive and noncompetitive NMDA antagonists block sensitization to methamphetamine. Pharmacol Biochem Behav. 1994;48:587–591.","DOI":"10.1016\/0091-3057(94)90318-2"},{"key":"28","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(95)00248-H"},{"key":"29","doi-asserted-by":"publisher","DOI":"10.1124\/pr.55.3.3"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Cole JC, Sumnall HR. The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA). Neurosci Biobehav Rev. 2003;27:199–217.","DOI":"10.1016\/S0149-7634(03)00031-9"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Baumgarten HG, Lachenmayer L. Serotonin neurotoxins – past and present. Neurotoxic Res. 2004;6:589–614.","DOI":"10.1007\/BF03033455"},{"issue":"3","key":"32","first-page":"427","volume":"19","year":"1998","ISSN":"https:\/\/id.crossref.org\/issn\/0161-813X","issn-type":"print"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Breier JM, Bankson MG, Yamamoto BK. L-tyrosine contributes to (+)-3,4-methylenedioxymethamphetamine-induced serotonin depletions. J Neurosci. 2006;26:290–299.","DOI":"10.1523\/JNEUROSCI.3353-05.2006"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Williams MT, Herring NR, Schaefer TL, Skelton MR, Campbell NG, Lipton JW, et al. Alterations in body temperature, corticosterone, and behavior following the administration of 5-methoxy-diisopropyltryptamine (“foxy”) to adult rats: a new drug of abuse. Neuropsychopharmacology. 2007;32:1404–1420.","DOI":"10.1038\/sj.npp.1301232"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T15:14:00Z","timestamp":1621437240000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/jphs\/106\/1\/106_FM0070141\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1254\/jphs.fm0070141","relation":{},"ISSN":["1347-8613","1347-8648"],"issn-type":[{"value":"1347-8613","type":"print"},{"value":"1347-8648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008]]}}}